Trials / Completed
CompletedNCT01564199
Phase I Pharmacokinetic Study (SALBLOCK)
Effect of Charcoal on Gastrointestinal Absorption of Salmeterol and Fluticasone Propionate.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to assess the extent to which the charcoal prevents the absorption of salmeterol and fluticasone via the GI tract. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve (AUCt).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | salmeterol / fluticasone propionate | 100/1000 μg oral capsule |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2012-03-27
- Last updated
- 2012-06-26
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT01564199. Inclusion in this directory is not an endorsement.